An Observational Study to Examine School Transition after Traumatic Brain Injury
The purpose of this study is to understand the best ways to help students return to school after brain injury of any severity. This is important to study because finding the best ways to help students go back to school right after brain injury, and over time, can help improve student success and recovery.
Your participation in the study would take place when you/your child begins the study and then at 3 months, 6 months, 12 months, 2 years (if applicable) and 3 years (if applicable) after the study starts.
• Students aged 5 to 18 years old
• In kindergarten through 12th grade
• Must Speak English
• Traumatic Brain Injury (TBI) of any severity
• Parent/caregiver is willing to share medical and academic information with the research team (all study activities are virtual/remote)
A Study to Examine Atropine for the Reduction of Nearsightedness (The CHAPERONE Study)
The purpose of this study to test the safety and effectiveness of atropine 0.1% and atropine 0.01% eye solutions. These drugs are being tested to see if they slow the worsening of nearsightedness. Children who participate in this study will be asked to use their assigned study medication every night and willing to attend visits at The Ohio State University of Optometry 1 month after starting treatment. These visits will continue for 6 months until the duration of the study ends. This study will take place over a 4-year time period.
· Children aged 3 to < 13 years old. · No previous use of medications related to myopia control. · Glasses and/or contact lens prescription between -1.00 and -6.00 diopters. Interested guardians who believe their child may be eligible should contact study coordinators to further determine eligibility
A Study Evaluating How Heart Disease Affects School Readiness in Children
The purpose of the p-SCHOLAR study is to learn about how congenital heart disease (CHD) might be related to school readiness and development in young children.
This is a single-study visit that will last approximately 3 hours and take place at Nationwide Children's Hospital.
During the 3-hour study visit, we will measure the child's thinking skills, knowledge of letters and numbers, and their behavior. We will also ask the caregiver to complete a set of surveys and a short interview about the child.
If the child is enrolled in a preschool or another educational program, their teacher will have the opportunity to participate in the study as well.
- Legal guardians and their child aged 4 or 5 years old
- Children who have not yet started kindergarten
- Children with no history of congenital heart defects (CHD), traumatic brain injury (TBI), or genetic conditions known to affect cognition
- Children with no severe hearing or vision impairments
- Children born full term (gestational age ≥ 37 weeks)
- Children and caregivers fluent in English
Measuring Sleep Problems in Children with Autism Spectrum Disorder (ASD)
The purpose of this study is to get a better understanding and improve measurement of sleep problems in children with Autism Spectrum Disorder (ASD).
Total time involved in study will be approximately 5 hours
- Parents of children with ASD, and
- Children with ASD ages 3-12, with mild, medium or major sleep problems either currently or in the past
- Children on medication can participate if the medicine dose is stable for at least one month
Child Categorization Study
The purpose of the study is to investigate the early development of attention, learning and memory; this is a multi-year study.
All sessions will take approximately 60-120 minutes to complete. This study will be conducted in our lab, and mandated OSU COVID safety protocol will be followed.
- Children who are 4 years old
- Have normal or corrected to normal vision
Child Memory Study
The purpose of this study is to understand how children sort new information using simple memory exercises with animated computer games.
All sessions will take approximately 25-45 minutes to complete. Participating children will play memory games on our touchscreens and computers. For on-campus sessions, mandated OSU COVID safety precautions will be followed.
- Children ages 4-9 years old
Perinatal Arterial Stroke: The I-ACQUIRE Study
Children who suffered a stroke before or shortly after being born that was caused by blockage of blood flow in an artery, it often results in the child showing some weakness on one side of their body.
With this study, we want to find out if a type of therapy may help children who have weakness on one side of their body due to perinatal arterial ischemic stroke, learn how to better use their weaker arm.
All children will be in the study for about 13 - 15 months. Some children may be in the study for a longer period, depending on which treatment they receive during Phase 1 of the study. The I-ACQUIRE therapy involves fun learning and play, self-help activities, and manipulating interesting toys and objects.
- Your child must be between the ages of 8 and 36 months old when beginning this study
- Your child must have suffered an a perinatal arterial ischemic stroke
- Upper limb weakness
- Parents must be able to participate at least 1x/week for therapy and 40-60 minutes/day at home
A Study Evaluating Occupational Therapy Interventions for Children with Autism Spectrum Disorders
We are actively recruiting typically developing children (ages 6 – 13 years) to participate in a new study looking at attention and sensory processing. In this study, we are investigating what occupational therapy practitioners are doing during therapy for children with autism and to see the effect of occupational therapy on brainwaves and behavior. We will identify differences in brainwaves in children with and without autism. You and your child will be asked to schedule one visit to the EEG lab at Ohio State University. Your visit will last about 2.5 hours and include an hour of EEG testing and one hour of paper-pencil game-like activities measuring attention. We need parent consent, and the parent/guardian will complete assessments about their child as well.
- Children with no autism or any other medical diagnosis - Your child is between 6 - 13 years of age
Hepatitis C Virus Immunity in Women and Children
This is a study to find out how pregnancy affects a mother’s immune system. (The “immune system” is the part of the body that fights germs.) This study is also to find out why some babies who are exposed to infections during pregnancy get infected and others do not.
To do this project we need to study some women and babies who are infected with the hepatitis C virus and others who are not. This will allow us to compare their immune systems.
You may be eligible to participate if you are:
PREGNANCY COHORT eligibility criteria:
1) Pregnant (enrollment preferably during 1st or 2nd trimester, but may occur as late as the delivery hospitalization)
2) HCV-RNA positive (#150) or HCV-RNA negative (#50)
3) Willing and able to attend all study visits
Exclusion criteria for mothers:
1) Inability to provide informed consent
2) Incarceration
Inclusion criteria for infants:
1) Child born to study mother
Exclusion criteria for infants:
1) In custody of county children’s services (Enrolled infants who are temporarily in custody of children’s services will not have further study blood draws, but lab results from blood tests ordered by their pediatrician may be followed to monitor the outcome of their HCV exposure. Infants who are later placed back in the custody of their mother or relative may be re-enrolled.)
NON-PREGNANCY COHORT eligibility criteria:
1) Willing and able to attend all study visits
Exclusion criteria:
1) Currently pregnant
2) Inability to provide informed consent
3) Incarceration
COVID-19 Determinants of Disease Severity, Perinatal Transmission, and Immune Response to COVID-19 Vaccine
To identify the factors that determine disease severity, immune development, and perinatal transmission in COVID-19 infections.
Inclusion criteria
Cohorts 1: Suspected/Infected Individuals (inpatient or outpatient)
1) All ages
2) Suspected or confirmed COVID-19 infection
3) Parents, guardians or patients over the age of 18 years of age must sign the informed consent; and children older than 9 years of age should sign assent, as required.
Cohort 2: Pregnant Women and/or their Infants*
1) Suspected or confirmed COVID-19 infection AND
2) Pregnant women in any stage of gestation, or within 14 days of a 20+ week gestation delivery; we may enroll mothers alone in situations where they choose for their newborn to not participate OR
3) Infants born to eligible mothers; in situations where the mother does not participate in the study, we may enroll infants born to infected women individually into this cohort
*Pregnant women without suspected or confirmed COVID-19 infection will also be enrolled as a healthy control group and will follow the same visit schedule.
Cohort 3 Vaccinated Children, Adults, Pregnant/Lactating Women and/or their Infants
• Pregnant/lactating women with intent to receive a COVID-19 vaccine; we may enroll mothers alone in situation where they choose for their newborn to not participate OR
• Infants born to eligible mothers; in situations where the mother chooses not to participate in the study, we may enroll their infant separately. OR
• Children/Adults of any age with intent to receive a COVID-19 vaccine
Cohort 4 Healthy Controls
• Anyone without an acute illness at the time of enrollment who agrees to participate in the study.
Exclusion criteria
a) Individuals who refuse participation in the study.
Pagination
- Previous page
- Page 2
- Next page